Business Context and Reporting Period
Company: Accuray Incorporated (ARAY)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2026
Business Overview: Accuray develops, manufactures, and sells radiation therapy systems, primarily the CyberKnife robotic platform and a helical portfolio (Accuray Stellar, Radixact, Accuray Helix, and Tomo C Systems). The company provides treatment delivery, planning, imaging, and data management solutions for cancer treatment.
Operational Status: The company is a smaller reporting company and an accelerated filer. It operates globally with manufacturing facilities in Madison, Wisconsin, and Chengdu, China.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 | Change |
|---|---|---|---|
| Net Revenue | $401.9 million | $458.5 million | (12)% |
| Gross Profit | $111.5 million | $147.0 million | (24)% |
| Gross Margin | 27.7% | 32.1% | -440 bps |
| Operating Loss | $(26.4) million | $7.8 million (Income) | Turn to Loss |
| Net Loss | $(49.2) million | $(1.6) million | Significant Increase |
| Cash and Cash Equivalents | $40.6 million | $57.4 million | (29)% |
| Total Debt (Outstanding Borrowings) | $205.3 million* | $182.0 million | Increased |
| Operating Cash Flow | $(7.0) million | $2.9 million | Turn to Negative |
*Includes $182.0M Term Loan, $5.0M Revolving Credit, $18.3M Delayed Draw, and $10.3M accumulated PIK interest.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 12% year-over-year, driven primarily by a 45% drop in China revenue ($68.1M vs. $124.5M) due to geopolitical tensions and tariff uncertainty. Product revenue fell 27% due to lower shipment volumes, while Services revenue grew 4%.
- Margin Compression: Gross margin declined to 27.7% from 32.1%. This was attributed to non-IEEPA tariff expenses, unfavorable product mix (fewer CyberKnife shipments to China), and increased logistics/material costs.
- Restructuring Charges: The company incurred $16.2 million in restructuring charges in FY2026 (none in FY2025) as part of a Transformation Plan to reduce costs and realign the organization. This included severance, third-party implementation costs, and asset impairments.
- Interest Expense Surge: Total interest expense increased 154% to $32.9 million, driven by the full-year impact of the June 2025 financing agreement, higher cash interest, accrued paid-in-kind (PIK) interest, and amortization of debt financing costs.
- Backlog Reduction: Order backlog decreased to $312.5 million from $427.0 million, reflecting significant age-outs ($128.8M) and cancellations ($10.2M) offset by gross orders of $191.9 million.
Guidance, Outlook, and Risks
- Transformation Plan: Management is executing a strategic plan to right-size the cost structure, outsource non-core activities, and optimize the workforce. The plan is substantially completed as of June 30, 2026.
- Liquidity and Financing:
- As of June 30, 2026, cash was $40.6 million. Management believes resources are sufficient for the next 12 months.
- Subsequent Event (July 29, 2026): Entered into a financing transaction involving $55.0 million of Series A Convertible Preferred Stock ($15M cash, $40M debt conversion). This includes a covenant holiday through December 31, 2027, and a conversion of the revolving credit facility to an asset-based lending structure.
- Nasdaq Compliance: The company received notice of non-compliance with the $1.00 minimum bid price requirement. It was granted an additional 180-day compliance period and transferred to the Nasdaq Capital Market. A reverse stock split is being evaluated.
- Key Risks:
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting (related to footnote schedules and ASC 606 adoption). One weakness remained unremediated as of June 30, 2026, resulting in an adverse opinion on internal controls.
- Geopolitics and Tariffs: Ongoing U.S.-China trade tensions and tariffs continue to impact China sales and gross margins. The company expects these headwinds to persist through at least fiscal 2027.
- Supply Chain: Inflation and supply chain constraints are increasing material and logistics costs, which the company cannot fully pass on to customers.
Investor Verification Checklist
- Internal Control Remediation: Verify the timeline and progress for remediating the remaining material weakness in internal controls over financial reporting.
- Financing Transaction Closing: Confirm the closing conditions for the July 2026 Series A Preferred Stock issuance, specifically stockholder approval and the implementation of the reverse stock split.
- China Revenue Trajectory: Monitor the impact of tariffs and geopolitical tensions on the China region, which represented 16% of revenue in FY2026 but dropped significantly from the prior year.
- Debt Covenant Compliance: Review the company's ability to meet the modified financial covenants (fixed charge coverage, leverage ratio) under the amended financing agreement, noting the covenant holiday through late 2027.
- Backlog Conversion: Assess the rate at which the remaining $312.5 million backlog converts to revenue, given the history of age-outs and cancellations.